Project/Area Number |
10680809
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Biomedical engineering/Biological material science
|
Research Institution | KOBE PHARMACEUTICAL UNIVERSITY |
Principal Investigator |
OTSUKA Makoto Kobe Pharmaceutical University, Associate Professor, 薬学部, 助教授 (90160548)
|
Co-Investigator(Kenkyū-buntansha) |
TAKASHI Nakamura Kyoto University, Professor, 大学院・医学研究科, 教授 (10201675)
|
Project Period (FY) |
1998 – 1999
|
Project Status |
Completed (Fiscal Year 1999)
|
Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 1999: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1998: ¥3,000,000 (Direct Cost: ¥3,000,000)
|
Keywords | Biomaterials / Bis-GMA / Drug delivery system / Cephalexin / Artificial bone / hydroxyapatite / bioaffinity / bone activity |
Research Abstract |
Effect of formulation of the bioactive bone cements on cephalexin (CEX) release from cement consisting of synthesis or natural polymers and apatite related ceramics powder was investigated. Bisphenol-α-glycidyl methacrylate (Bis-GMA), triethylene-glycol dimethacrylate (TEGDMA) resin and apatite- and wollastonite-containing glass-ceramic (A-W GC) powder containing CEX powder hardened within 5 min after mixing with Bis-GMA/TEGDMA resin, and furthermore its compressive strength was expected to be higher than that of polymethylmethacrylate cement. In vitro CEX release from bioactive bone cement pellets in simulated body fluid at pH 7.25 and 37℃ continued for more than 2 weeks. The drug release rate increased with increasing amount of CEX in the mixture. All of the drug release profiles the Higuchi equation at the initial stage, but not at later stages. As hydroxyapatite was precipitated out on the cement surface, the drug release rate decreased. These results suggest that the CEX release rate from bioactive bone cement could be controlled by varying the amount of drug in the cement system.
|